Press Releases
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
– OMNIA-1 is a Phase I/II study to determine the efficacy of ANV419 as monotherapy and in combination with anti-PD1 or anti-CTLA4 antibodies in advanced melanoma –
read more
Anaveon appoints Dr Eduard Gasal as Chief Medical Officer
Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO).
read more
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase I study of ANV419 in patients with solid tumors at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA
read more
Anaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA.
read more
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022
Anaveon appoints Dr Gary Phillips as Chief Business Officer
Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions.
read more
Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419
Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma.
read more
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
As of the March 11, 2022 data cut-off date, 16 patients in 7 dosing cohorts with different types of progressing cancer received ANV419 every 14 days. ANV419, administered intravenously over 15 minutes was exceptionally well tolerated with most patients experiencing a mild Grade 1 infusion-related reaction with chills and low-grade fever a few hours after dosing, which resolved with antipyretic treatment. No patients experienced a Grade 3 or worse drug related AE and no patients have withdrawn from study due to AEs. No dose limiting toxicities have been observed.
read more